Skip to Content

Asset & Pipeline Development Planning

How we help with Asset & Pipeline Development Planning

Asset & pipeline development planning is about streamlining a development strategy, highlighting efficient development pathways, and optimizing the speed and efficiency of asset development. Halloran uses an integrated, cross-functional lens to provide benchmarking, assumptions, risk analysis, and resource planning with coordinated timelines and budgets for our client’s programs. This plan is broken out by key activities and functional areas across clinical development, regulatory, chemistry manufacturing and controls (CMC), and non-clinical development.


Throughout the creation of the Asset & Pipeline Development Plan, we become our client’s trusted partner to accelerate progress and are fully prepared to lead the implementation of the plan, if desired.

RELATED INSIGHTS

  • This comprehensive webinar offers an insightful exploration into the intricate landscape of New Drug Applications (NDAs) and Biologics License Applications (BLAs), elucidating the pivotal regulatory procedures imperative for pharmaceutical companies seeking approval for novel drugs and biologics. Its primary objective is to equip participants with the requisite knowledge and resources essential for navigating the intricate […]

  • The U.S. Food and Drug Administration’s (FDA) draft guidance, Master Protocols for Drug and Biological Product Development, released on December 21, 2023, provides expanded recommendations on the design and analysis of trials conducted under a master protocol. A master protocol is a protocol designed with multiple substudies, which may have different objectives and involve coordinated […]

  • Small life science companies often need to ‘do more with less.’ Leaders of these companies must seek ways to trim costs without sacrificing quality and speed. As you build your development team, you may be tempted to forgo hiring a Program Manager, but that decision may create less-than-desirable results.  Leaders of life science companies, especially […]